Member Info for Laura2022

Courtesy of a previous message last weekend

With reference to the proposed EUDA-Theoremrx merger, the original LOI was signed on 4th October and announced on 5th October. The LOI provided for a 30 day exclusivity period with the option of a 15 day extension at the agreement of both parties. I believe that if it were 'working days' then surely it would have specified this

My interpretation is that the 30 day exclusivity period expired on 3rd November and we are now well into the extension period with the final date for a news release being 18th November. As the 18th November falls on a Saturday, I would expect news by close of business in the US Friday night

Physiomics plc (AIM: PYC), is pleased to announce that, following today's announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company's personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT.

Thankyòu for explaining

C and h ?

Msuk

Looks like a coiled spring ? Is that the technical term?

Yes shenners

I have been buying RQIH at 10p to 11p

Thanks Trench

Hopefully the AGM next week will give us more details if they do q AGM statement/presentation

Shenners

11p and £40mln market value is ludicrous

This should be 30p-50p

For the first time ever, the Company has felt in a position to quantify the value of its pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August

4 trades totalling nearly £800,000 at 3.52pm

Looks like whatever is going on is soon to reveal itself

Thanks Ralph

Also a presentation this Friday 17th

Huge trades delayed

£1.9mln market cap with c.£750,000 cash and now a £170k Innovate Grant

£1mln pipeline of deals for 2023/24 on top of the 4 or 5 won since July 2023

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

Excellent news

It's the news released last Friday

This Friday 17th Nov there will be a further presentation

£170k funding which is nearly 10% of the current market cap

At these levels as the insurance sector consolidates

I have added more

This should be 50p+

£40mln /11p people share I far too cheap

I have be buying for the last 2 weeks

You think £1.00 per share for their assets control madness?

Act as Chairman and Interim Chief Executive Officer of R&Q and Paul Bradbrook, currently Chief Accounting Officer of R&Q, will become Chief Financial Officer of R&Q and a member of the Board, subject to customary approvals. The Presentation also outlines R&Q Legacy's wider management team and its significant collective experience. The management team is excited by the growth opportunity it sees within R&Q Legacy's addressable market. In the Presentation, management has set out three strategic priorities through which it believes R&Q Legacy can deliver growth and value creation:

·      Grow fee income

·      Reduce expenses

·      Decrease balance sheet volatility

 

Underpinning these priorities are strategic initiatives currently underway to de-risk the R&Q Legacy portfolio including:

·      A possible LPT (Loss Portfolio Transfer) or ADC (Adverse Development Cover) on certain portfolios

·      The sale of non-core assets

·      The sale, or securitization, of back book legacy liabilities

 

In the Presentation, R&Q provides an associated plan for the R&Q Legacy business, although it should be stressed that the ability of R&Q Legacy to achieve such objectives depends on many factors, including not least a successful closing of the Sale and the paydown of R&Q debt. This plan includes that:

·      The refocused business and strategy is expected to deliver operating profitability by full year 2025

·      Fee income is targeted to be doubled in 2025 compared to H1 2023 annualised

·      Expenses are anticipated to be reduced by 15% to 20% in 2025 relative to an adjusted annualised H1 2023 expense base that includes certain assumptions around Legacy's standalone cost structure

·      As R&Q returns to profitability, it will review its dividend policy, subject to constraints due to relationships with lenders, regulators and preferred shareholders

 

The Presentation also outlines R&Q's expectation of $100m+ of cumulative surplus capital to be generated over the next ~5 years as claims payments are made, releasing capital held against reserves. This is in addition to the estimated $40m - $80m of additional collateral R&Q will be required to hold against existing legacy exposure retained by Accredited, which R&Q expects to be released and available over the next 5+ years as the underlying exposures are reduced and eliminated

Feb 2021 original PYC and VAL deal

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.

Val CEO Q and A October 2023

"We have every indication we will be able to put out a substantial update beofe the end of the year - if that wasn't the case then clearly we would have already announced that wasn't the case.. we have a good degree of certainty."

"When the sublicense is signed, we will then be able to invoice them (TheoremRX) for the time that has been spent under the service agreement.. along with the upfront payments and the early milestone payments"